NEWS
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Acumen Pharmaceuticals (NASDAQ: ABOS) presented new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference 2024.
The research focuses on patient experiences, biomarker data, and a new ultra-sensitive assay for measuring sabirnetug in cerebrospinal fluid. Sabirnetug, a humanized monoclonal antibody, targets toxic soluble amyloid beta oligomers (AβOs) in early symptomatic Alzheimer's disease (AD).
Key findings include:
Patient interviews revealed desires for treatments that slow disease progression and maintain cognitive abilities
Sabirnetug significantly lowered CSF levels of synaptic proteins, supporting its mechanism of action
A new ultra-sensitive assay was developed to detect sabirnetug in CSF
Acumen is currently conducting the Phase 2 ALTITUDE-AD trial to further evaluate sabirnetug's efficacy and safety in early AD patients.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2553Followers
107Following
28KVisitors
Follow
Lnova : Thank you for sharing